# Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

> **NCT00587873** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Hodgkin's Disease

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Leucovorin calcium
- **DRUG:** 6-Thioguanine

## Key facts

- **NCT ID:** NCT00587873
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-03
- **Primary completion:** 2003-12
- **Final completion:** 2009-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2009-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00587873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00587873, "Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00587873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*